Phase I/II Study of Trastuzumab in Combination With Everolimus (RAD001) in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Progressed on Trastuzumab-Based Therapy
Phuong K. Morrow(Cornell University), Francisco J. Esteva(Northwell Health)
Cited by 211
Related Papers
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
|Cancer Cell|2004|1.9k
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers
|Clinical Chemistry|2008|1.1k
Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients
|Cancer|2011|291
PTEN, PIK3CA, p-AKT, and p-p70S6K Status
|American Journal Of Pathology|2010|285
Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells
|Breast Cancer Research|2010|137